# Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease

> **NCT03625401** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Hisun Pharmaceutical Co. Ltd.** · enrollment: 55 (estimated)

## Conditions studied

- Alzheimer Disease, Early Onset

## Interventions

- **DRUG:** AD-35 60mg group
- **DRUG:** Placebo group

## Key facts

- **NCT ID:** NCT03625401
- **Lead sponsor:** Zhejiang Hisun Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-04
- **Primary completion:** 2020-12
- **Final completion:** 2020-12-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2020-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03625401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03625401, "Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03625401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*